MindBio Therapeutics (XCNQ:MBIO) Accounts Payable & Accrued Expense : C$0.46 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Accounts Payable & Accrued Expense?

MindBio Therapeutics's quarterly accounts payable & accrued expense increased from Sep. 2023 (C$0.45 Mil) to Dec. 2023 (C$0.45 Mil) and increased from Dec. 2023 (C$0.45 Mil) to Mar. 2024 (C$0.46 Mil).

MindBio Therapeutics's annual accounts payable & accrued expense increased from Jun. 2021 (C$0.44 Mil) to Jun. 2022 (C$1.07 Mil) but then declined from Jun. 2022 (C$1.07 Mil) to Jun. 2023 (C$0.58 Mil).

MindBio Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for MindBio Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Accounts Payable & Accrued Expense Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Accounts Payable & Accrued Expense

0.44

1.07

0.58

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial					0.20	0.58	0.45	0.45	0.46

MindBio Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.